COVID-19 Impact on Global Indolent Lymphoma Treatment Market Size, Status and Forecast 2020-2026

September 2020 | 92 pages | ID: C919D0118CE5EN
QYResearch

Abstracts

This report focuses on the global Indolent Lymphoma Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Indolent Lymphoma Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Altor BioScience Corporation
• Amgen Inc.
• Astellas Pharma Inc.
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• Incyte Corporation
• Infinity Pharmaceuticals, Inc.
• Juno Therapeutics Inc.
• MedImmune, LLC

Market segment by Type, the product can be split into

• BI-836826
• ALT-803
• BMS-986016
• CC-122
• Others

Market segment by Application, split into

• Hospital
• Clinic
• Others

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Indolent Lymphoma Treatment status, future forecast, growth opportunity, key market and key players.
• To present the Indolent Lymphoma Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Indolent Lymphoma Treatment are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Indolent Lymphoma Treatment Revenue
1.4 Market Analysis by Type
  1.4.1 Global Indolent Lymphoma Treatment Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 BI-836826
  1.4.3 ALT-803
  1.4.4 BMS-986016
  1.4.5 CC-122
  1.4.6 Others
1.5 Market by Application
  1.5.1 Global Indolent Lymphoma Treatment Market Share by Application: 2020 VS 2026
  1.5.2 Hospital
  1.5.3 Clinic
  1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): Indolent Lymphoma Treatment Industry Impact
  1.6.1 How the Covid-19 is Affecting the Indolent Lymphoma Treatment Industry
    1.6.1.1 Indolent Lymphoma Treatment Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Indolent Lymphoma Treatment Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Indolent Lymphoma Treatment Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Indolent Lymphoma Treatment Market Perspective (2015-2026)
2.2 Indolent Lymphoma Treatment Growth Trends by Regions
  2.2.1 Indolent Lymphoma Treatment Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Indolent Lymphoma Treatment Historic Market Share by Regions (2015-2020)
  2.2.3 Indolent Lymphoma Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Indolent Lymphoma Treatment Market Growth Strategy
  2.3.6 Primary Interviews with Key Indolent Lymphoma Treatment Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Indolent Lymphoma Treatment Players by Market Size
  3.1.1 Global Top Indolent Lymphoma Treatment Players by Revenue (2015-2020)
  3.1.2 Global Indolent Lymphoma Treatment Revenue Market Share by Players (2015-2020)
  3.1.3 Global Indolent Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Indolent Lymphoma Treatment Market Concentration Ratio
  3.2.1 Global Indolent Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Indolent Lymphoma Treatment Revenue in 2019
3.3 Indolent Lymphoma Treatment Key Players Head office and Area Served
3.4 Key Players Indolent Lymphoma Treatment Product Solution and Service
3.5 Date of Enter into Indolent Lymphoma Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Indolent Lymphoma Treatment Historic Market Size by Type (2015-2020)
4.2 Global Indolent Lymphoma Treatment Forecasted Market Size by Type (2021-2026)

5 INDOLENT LYMPHOMA TREATMENT BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Indolent Lymphoma Treatment Market Size by Application (2015-2020)
5.2 Global Indolent Lymphoma Treatment Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Indolent Lymphoma Treatment Market Size (2015-2020)
6.2 Indolent Lymphoma Treatment Key Players in North America (2019-2020)
6.3 North America Indolent Lymphoma Treatment Market Size by Type (2015-2020)
6.4 North America Indolent Lymphoma Treatment Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Indolent Lymphoma Treatment Market Size (2015-2020)
7.2 Indolent Lymphoma Treatment Key Players in Europe (2019-2020)
7.3 Europe Indolent Lymphoma Treatment Market Size by Type (2015-2020)
7.4 Europe Indolent Lymphoma Treatment Market Size by Application (2015-2020)

8 CHINA

8.1 China Indolent Lymphoma Treatment Market Size (2015-2020)
8.2 Indolent Lymphoma Treatment Key Players in China (2019-2020)
8.3 China Indolent Lymphoma Treatment Market Size by Type (2015-2020)
8.4 China Indolent Lymphoma Treatment Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Indolent Lymphoma Treatment Market Size (2015-2020)
9.2 Indolent Lymphoma Treatment Key Players in Japan (2019-2020)
9.3 Japan Indolent Lymphoma Treatment Market Size by Type (2015-2020)
9.4 Japan Indolent Lymphoma Treatment Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Indolent Lymphoma Treatment Market Size (2015-2020)
10.2 Indolent Lymphoma Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Indolent Lymphoma Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Indolent Lymphoma Treatment Market Size by Application (2015-2020)

11 INDIA

11.1 India Indolent Lymphoma Treatment Market Size (2015-2020)
11.2 Indolent Lymphoma Treatment Key Players in India (2019-2020)
11.3 India Indolent Lymphoma Treatment Market Size by Type (2015-2020)
11.4 India Indolent Lymphoma Treatment Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Indolent Lymphoma Treatment Market Size (2015-2020)
12.2 Indolent Lymphoma Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Indolent Lymphoma Treatment Market Size by Type (2015-2020)
12.4 Central & South America Indolent Lymphoma Treatment Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Altor BioScience Corporation
  13.1.1 Altor BioScience Corporation Company Details
  13.1.2 Altor BioScience Corporation Business Overview and Its Total Revenue
  13.1.3 Altor BioScience Corporation Indolent Lymphoma Treatment Introduction
  13.1.4 Altor BioScience Corporation Revenue in Indolent Lymphoma Treatment Business (2015-2020))
  13.1.5 Altor BioScience Corporation Recent Development
13.2 Amgen Inc.
  13.2.1 Amgen Inc. Company Details
  13.2.2 Amgen Inc. Business Overview and Its Total Revenue
  13.2.3 Amgen Inc. Indolent Lymphoma Treatment Introduction
  13.2.4 Amgen Inc. Revenue in Indolent Lymphoma Treatment Business (2015-2020)
  13.2.5 Amgen Inc. Recent Development
13.3 Astellas Pharma Inc.
  13.3.1 Astellas Pharma Inc. Company Details
  13.3.2 Astellas Pharma Inc. Business Overview and Its Total Revenue
  13.3.3 Astellas Pharma Inc. Indolent Lymphoma Treatment Introduction
  13.3.4 Astellas Pharma Inc. Revenue in Indolent Lymphoma Treatment Business (2015-2020)
  13.3.5 Astellas Pharma Inc. Recent Development
13.4 Bayer AG
  13.4.1 Bayer AG Company Details
  13.4.2 Bayer AG Business Overview and Its Total Revenue
  13.4.3 Bayer AG Indolent Lymphoma Treatment Introduction
  13.4.4 Bayer AG Revenue in Indolent Lymphoma Treatment Business (2015-2020)
  13.4.5 Bayer AG Recent Development
13.5 Boehringer Ingelheim GmbH
  13.5.1 Boehringer Ingelheim GmbH Company Details
  13.5.2 Boehringer Ingelheim GmbH Business Overview and Its Total Revenue
  13.5.3 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Introduction
  13.5.4 Boehringer Ingelheim GmbH Revenue in Indolent Lymphoma Treatment Business (2015-2020)
  13.5.5 Boehringer Ingelheim GmbH Recent Development
13.6 Bristol-Myers Squibb Company
  13.6.1 Bristol-Myers Squibb Company Company Details
  13.6.2 Bristol-Myers Squibb Company Business Overview and Its Total Revenue
  13.6.3 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Introduction
  13.6.4 Bristol-Myers Squibb Company Revenue in Indolent Lymphoma Treatment Business (2015-2020)
  13.6.5 Bristol-Myers Squibb Company Recent Development
13.7 Celgene Corporation
  13.7.1 Celgene Corporation Company Details
  13.7.2 Celgene Corporation Business Overview and Its Total Revenue
  13.7.3 Celgene Corporation Indolent Lymphoma Treatment Introduction
  13.7.4 Celgene Corporation Revenue in Indolent Lymphoma Treatment Business (2015-2020)
  13.7.5 Celgene Corporation Recent Development
13.8 Eli Lilly and Company
  13.8.1 Eli Lilly and Company Company Details
  13.8.2 Eli Lilly and Company Business Overview and Its Total Revenue
  13.8.3 Eli Lilly and Company Indolent Lymphoma Treatment Introduction
  13.8.4 Eli Lilly and Company Revenue in Indolent Lymphoma Treatment Business (2015-2020)
  13.8.5 Eli Lilly and Company Recent Development
13.9 F. Hoffmann-La Roche Ltd.
  13.9.1 F. Hoffmann-La Roche Ltd. Company Details
  13.9.2 F. Hoffmann-La Roche Ltd. Business Overview and Its Total Revenue
  13.9.3 F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Introduction
  13.9.4 F. Hoffmann-La Roche Ltd. Revenue in Indolent Lymphoma Treatment Business (2015-2020)
  13.9.5 F. Hoffmann-La Roche Ltd. Recent Development
13.10 Gilead Sciences, Inc.
  13.10.1 Gilead Sciences, Inc. Company Details
  13.10.2 Gilead Sciences, Inc. Business Overview and Its Total Revenue
  13.10.3 Gilead Sciences, Inc. Indolent Lymphoma Treatment Introduction
  13.10.4 Gilead Sciences, Inc. Revenue in Indolent Lymphoma Treatment Business (2015-2020)
  13.10.5 Gilead Sciences, Inc. Recent Development
13.11 Incyte Corporation
  10.11.1 Incyte Corporation Company Details
  10.11.2 Incyte Corporation Business Overview and Its Total Revenue
  10.11.3 Incyte Corporation Indolent Lymphoma Treatment Introduction
  10.11.4 Incyte Corporation Revenue in Indolent Lymphoma Treatment Business (2015-2020)
  10.11.5 Incyte Corporation Recent Development
13.12 Infinity Pharmaceuticals, Inc.
  10.12.1 Infinity Pharmaceuticals, Inc. Company Details
  10.12.2 Infinity Pharmaceuticals, Inc. Business Overview and Its Total Revenue
  10.12.3 Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Introduction
  10.12.4 Infinity Pharmaceuticals, Inc. Revenue in Indolent Lymphoma Treatment Business (2015-2020)
  10.12.5 Infinity Pharmaceuticals, Inc. Recent Development
13.13 Juno Therapeutics Inc.
  10.13.1 Juno Therapeutics Inc. Company Details
  10.13.2 Juno Therapeutics Inc. Business Overview and Its Total Revenue
  10.13.3 Juno Therapeutics Inc. Indolent Lymphoma Treatment Introduction
  10.13.4 Juno Therapeutics Inc. Revenue in Indolent Lymphoma Treatment Business (2015-2020)
  10.13.5 Juno Therapeutics Inc. Recent Development
13.14 MedImmune, LLC
  10.14.1 MedImmune, LLC Company Details
  10.14.2 MedImmune, LLC Business Overview and Its Total Revenue
  10.14.3 MedImmune, LLC Indolent Lymphoma Treatment Introduction
  10.14.4 MedImmune, LLC Revenue in Indolent Lymphoma Treatment Business (2015-2020)
  10.14.5 MedImmune, LLC Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Indolent Lymphoma Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Indolent Lymphoma Treatment Revenue
Table 3. Ranking of Global Top Indolent Lymphoma Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Indolent Lymphoma Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of BI-836826
Table 6. Key Players of ALT-803
Table 7. Key Players of BMS-986016
Table 8. Key Players of CC-122
Table 9. Key Players of Others
Table 10. COVID-19 Impact Global Market: (Four Indolent Lymphoma Treatment Market Size Forecast Scenarios)
Table 11. Opportunities and Trends for Indolent Lymphoma Treatment Players in the COVID-19 Landscape
Table 12. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 13. Key Regions/Countries Measures against Covid-19 Impact
Table 14. Proposal for Indolent Lymphoma Treatment Players to Combat Covid-19 Impact
Table 15. Global Indolent Lymphoma Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 16. Global Indolent Lymphoma Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 17. Global Indolent Lymphoma Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 18. Global Indolent Lymphoma Treatment Market Share by Regions (2015-2020)
Table 19. Global Indolent Lymphoma Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 20. Global Indolent Lymphoma Treatment Market Share by Regions (2021-2026)
Table 21. Market Top Trends
Table 22. Key Drivers: Impact Analysis
Table 23. Key Challenges
Table 24. Indolent Lymphoma Treatment Market Growth Strategy
Table 25. Main Points Interviewed from Key Indolent Lymphoma Treatment Players
Table 26. Global Indolent Lymphoma Treatment Revenue by Players (2015-2020) (Million US$)
Table 27. Global Indolent Lymphoma Treatment Market Share by Players (2015-2020)
Table 28. Global Top Indolent Lymphoma Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Indolent Lymphoma Treatment as of 2019)
Table 29. Global Indolent Lymphoma Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 30. Key Players Headquarters and Area Served
Table 31. Key Players Indolent Lymphoma Treatment Product Solution and Service
Table 32. Date of Enter into Indolent Lymphoma Treatment Market
Table 33. Mergers & Acquisitions, Expansion Plans
Table 34. Global Indolent Lymphoma Treatment Market Size by Type (2015-2020) (Million US$)
Table 35. Global Indolent Lymphoma Treatment Market Size Share by Type (2015-2020)
Table 36. Global Indolent Lymphoma Treatment Revenue Market Share by Type (2021-2026)
Table 37. Global Indolent Lymphoma Treatment Market Size Share by Application (2015-2020)
Table 38. Global Indolent Lymphoma Treatment Market Size by Application (2015-2020) (Million US$)
Table 39. Global Indolent Lymphoma Treatment Market Size Share by Application (2021-2026)
Table 40. North America Key Players Indolent Lymphoma Treatment Revenue (2019-2020) (Million US$)
Table 41. North America Key Players Indolent Lymphoma Treatment Market Share (2019-2020)
Table 42. North America Indolent Lymphoma Treatment Market Size by Type (2015-2020) (Million US$)
Table 43. North America Indolent Lymphoma Treatment Market Share by Type (2015-2020)
Table 44. North America Indolent Lymphoma Treatment Market Size by Application (2015-2020) (Million US$)
Table 45. North America Indolent Lymphoma Treatment Market Share by Application (2015-2020)
Table 46. Europe Key Players Indolent Lymphoma Treatment Revenue (2019-2020) (Million US$)
Table 47. Europe Key Players Indolent Lymphoma Treatment Market Share (2019-2020)
Table 48. Europe Indolent Lymphoma Treatment Market Size by Type (2015-2020) (Million US$)
Table 49. Europe Indolent Lymphoma Treatment Market Share by Type (2015-2020)
Table 50. Europe Indolent Lymphoma Treatment Market Size by Application (2015-2020) (Million US$)
Table 51. Europe Indolent Lymphoma Treatment Market Share by Application (2015-2020)
Table 52. China Key Players Indolent Lymphoma Treatment Revenue (2019-2020) (Million US$)
Table 53. China Key Players Indolent Lymphoma Treatment Market Share (2019-2020)
Table 54. China Indolent Lymphoma Treatment Market Size by Type (2015-2020) (Million US$)
Table 55. China Indolent Lymphoma Treatment Market Share by Type (2015-2020)
Table 56. China Indolent Lymphoma Treatment Market Size by Application (2015-2020) (Million US$)
Table 57. China Indolent Lymphoma Treatment Market Share by Application (2015-2020)
Table 58. Japan Key Players Indolent Lymphoma Treatment Revenue (2019-2020) (Million US$)
Table 59. Japan Key Players Indolent Lymphoma Treatment Market Share (2019-2020)
Table 60. Japan Indolent Lymphoma Treatment Market Size by Type (2015-2020) (Million US$)
Table 61. Japan Indolent Lymphoma Treatment Market Share by Type (2015-2020)
Table 62. Japan Indolent Lymphoma Treatment Market Size by Application (2015-2020) (Million US$)
Table 63. Japan Indolent Lymphoma Treatment Market Share by Application (2015-2020)
Table 64. Southeast Asia Key Players Indolent Lymphoma Treatment Revenue (2019-2020) (Million US$)
Table 65. Southeast Asia Key Players Indolent Lymphoma Treatment Market Share (2019-2020)
Table 66. Southeast Asia Indolent Lymphoma Treatment Market Size by Type (2015-2020) (Million US$)
Table 67. Southeast Asia Indolent Lymphoma Treatment Market Share by Type (2015-2020)
Table 68. Southeast Asia Indolent Lymphoma Treatment Market Size by Application (2015-2020) (Million US$)
Table 69. Southeast Asia Indolent Lymphoma Treatment Market Share by Application (2015-2020)
Table 70. India Key Players Indolent Lymphoma Treatment Revenue (2019-2020) (Million US$)
Table 71. India Key Players Indolent Lymphoma Treatment Market Share (2019-2020)
Table 72. India Indolent Lymphoma Treatment Market Size by Type (2015-2020) (Million US$)
Table 73. India Indolent Lymphoma Treatment Market Share by Type (2015-2020)
Table 74. India Indolent Lymphoma Treatment Market Size by Application (2015-2020) (Million US$)
Table 75. India Indolent Lymphoma Treatment Market Share by Application (2015-2020)
Table 76. Central & South America Key Players Indolent Lymphoma Treatment Revenue (2019-2020) (Million US$)
Table 77. Central & South America Key Players Indolent Lymphoma Treatment Market Share (2019-2020)
Table 78. Central & South America Indolent Lymphoma Treatment Market Size by Type (2015-2020) (Million US$)
Table 79. Central & South America Indolent Lymphoma Treatment Market Share by Type (2015-2020)
Table 80. Central & South America Indolent Lymphoma Treatment Market Size by Application (2015-2020) (Million US$)
Table 81. Central & South America Indolent Lymphoma Treatment Market Share by Application (2015-2020)
Table 82. Altor BioScience Corporation Company Details
Table 83. Altor BioScience Corporation Business Overview
Table 84. Altor BioScience Corporation Product
Table 85. Altor BioScience Corporation Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US$)
Table 86. Altor BioScience Corporation Recent Development
Table 87. Amgen Inc. Company Details
Table 88. Amgen Inc. Business Overview
Table 89. Amgen Inc. Product
Table 90. Amgen Inc. Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US$)
Table 91. Amgen Inc. Recent Development
Table 92. Astellas Pharma Inc. Company Details
Table 93. Astellas Pharma Inc. Business Overview
Table 94. Astellas Pharma Inc. Product
Table 95. Astellas Pharma Inc. Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US$)
Table 96. Astellas Pharma Inc. Recent Development
Table 97. Bayer AG Company Details
Table 98. Bayer AG Business Overview
Table 99. Bayer AG Product
Table 100. Bayer AG Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US$)
Table 101. Bayer AG Recent Development
Table 102. Boehringer Ingelheim GmbH Company Details
Table 103. Boehringer Ingelheim GmbH Business Overview
Table 104. Boehringer Ingelheim GmbH Product
Table 105. Boehringer Ingelheim GmbH Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US$)
Table 106. Boehringer Ingelheim GmbH Recent Development
Table 107. Bristol-Myers Squibb Company Company Details
Table 108. Bristol-Myers Squibb Company Business Overview
Table 109. Bristol-Myers Squibb Company Product
Table 110. Bristol-Myers Squibb Company Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US$)
Table 111. Bristol-Myers Squibb Company Recent Development
Table 112. Celgene Corporation Company Details
Table 113. Celgene Corporation Business Overview
Table 114. Celgene Corporation Product
Table 115. Celgene Corporation Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US$)
Table 116. Celgene Corporation Recent Development
Table 117. Eli Lilly and Company Business Overview
Table 118. Eli Lilly and Company Product
Table 119. Eli Lilly and Company Company Details
Table 120. Eli Lilly and Company Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US$)
Table 121. Eli Lilly and Company Recent Development
Table 122. F. Hoffmann-La Roche Ltd. Company Details
Table 123. F. Hoffmann-La Roche Ltd. Business Overview
Table 124. F. Hoffmann-La Roche Ltd. Product
Table 125. F. Hoffmann-La Roche Ltd. Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US$)
Table 126. F. Hoffmann-La Roche Ltd. Recent Development
Table 127. Gilead Sciences, Inc. Company Details
Table 128. Gilead Sciences, Inc. Business Overview
Table 129. Gilead Sciences, Inc. Product
Table 130. Gilead Sciences, Inc. Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US$)
Table 131. Gilead Sciences, Inc. Recent Development
Table 132. Incyte Corporation Company Details
Table 133. Incyte Corporation Business Overview
Table 134. Incyte Corporation Product
Table 135. Incyte Corporation Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US$)
Table 136. Incyte Corporation Recent Development
Table 137. Infinity Pharmaceuticals, Inc. Company Details
Table 138. Infinity Pharmaceuticals, Inc. Business Overview
Table 139. Infinity Pharmaceuticals, Inc. Product
Table 140. Infinity Pharmaceuticals, Inc. Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US$)
Table 141. Infinity Pharmaceuticals, Inc. Recent Development
Table 142. Juno Therapeutics Inc. Company Details
Table 143. Juno Therapeutics Inc. Business Overview
Table 144. Juno Therapeutics Inc. Product
Table 145. Juno Therapeutics Inc. Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US$)
Table 146. Juno Therapeutics Inc. Recent Development
Table 147. MedImmune, LLC Company Details
Table 148. MedImmune, LLC Business Overview
Table 149. MedImmune, LLC Product
Table 150. MedImmune, LLC Revenue in Indolent Lymphoma Treatment Business (2015-2020) (Million US$)
Table 151. MedImmune, LLC Recent Development
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Indolent Lymphoma Treatment Market Share by Type: 2020 VS 2026
Figure 2. BI-836826 Features
Figure 3. ALT-803 Features
Figure 4. BMS-986016 Features
Figure 5. CC-122 Features
Figure 6. Others Features
Figure 7. Global Indolent Lymphoma Treatment Market Share by Application: 2020 VS 2026
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Indolent Lymphoma Treatment Report Years Considered
Figure 12. Global Indolent Lymphoma Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Indolent Lymphoma Treatment Market Share by Regions: 2020 VS 2026
Figure 14. Global Indolent Lymphoma Treatment Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Indolent Lymphoma Treatment Market Share by Players in 2019
Figure 17. Global Top Indolent Lymphoma Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Indolent Lymphoma Treatment as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Indolent Lymphoma Treatment Revenue in 2019
Figure 19. North America Indolent Lymphoma Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Indolent Lymphoma Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Indolent Lymphoma Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Indolent Lymphoma Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Indolent Lymphoma Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Indolent Lymphoma Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Indolent Lymphoma Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Altor BioScience Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Altor BioScience Corporation Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)
Figure 28. Amgen Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Amgen Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)
Figure 30. Astellas Pharma Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Astellas Pharma Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)
Figure 32. Bayer AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Bayer AG Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)
Figure 34. Boehringer Ingelheim GmbH Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Boehringer Ingelheim GmbH Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)
Figure 36. Bristol-Myers Squibb Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Bristol-Myers Squibb Company Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)
Figure 38. Celgene Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Celgene Corporation Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)
Figure 40. Eli Lilly and Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Eli Lilly and Company Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)
Figure 42. F. Hoffmann-La Roche Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)
Figure 44. Gilead Sciences, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Gilead Sciences, Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)
Figure 46. Incyte Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Incyte Corporation Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)
Figure 48. Infinity Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Infinity Pharmaceuticals, Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)
Figure 50. Juno Therapeutics Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Juno Therapeutics Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)
Figure 52. MedImmune, LLC Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. MedImmune, LLC Revenue Growth Rate in Indolent Lymphoma Treatment Business (2015-2020)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed